Promising HIV vaccine candidate passes early safety check in 57 volunteers

NCT ID NCT06033209

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This early-stage trial tested a new HIV vaccine candidate in 57 healthy adults without HIV. The goal was to see if the vaccine is safe and whether it triggers a specific immune response that could help fight the virus. Researchers used a special adjuvant to boost the vaccine's effect and compared different doses and schedules.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Atlanta - Hope Clinic

Decatur, Georgia, 30030, United States
Bridge HIV CRS

San Francisco, California, 94102, United States
Brigham & Women's Hospital

Boston, Massachusetts, 02115, United States
Columbia University Medical Center

New York, New York, 100032, United States
New York Blood Center

New York, New York, 10065, United States
Penn Prevention CRS [Site ID: 30310]

Philadelphia, Pennsylvania, 19104, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States
Vanderbilt Institute for Infection, Immunology and Inflammation

Nashville, Tennessee, 37232-2582, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.